Disc Medicine Inc

Disc Medicine is a Watertown, Massachusetts–based clinical-stage biopharmaceutical company built around a single, unusually coherent scientific thesis: that a small number of fundamental control points in red-blood-cell biology — heme biosynthesis and iron homeostasis, mediated by hepcidin — can be pharmacologically tuned in either direction to treat a wide spectrum of haematologic disease. The company operates an in-licensing-and-develop model rather than a discovery-platform model, having assembled its three clinical assets from Roche (bitopertin), AbbVie (selcodebart/DISC-0974 and DISC-0998) and Mabwell Therapeutics (DISC-3405). It has no products approved and no revenue. Its near-term valuation is dominated by a single binary: the Q4 2026 topline readout of the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, which follows a February 2026 Complete Response Letter. Behind that sits a genuine second act in myeloproliferative neoplasms. With approximately $718 million of liquidity at 30 June 2026 and runway into 2029, Disc is unusually well-capitalised for its stage.

What the company does. Disc Medicine discovers, in-licenses, develops and intends to commercialise novel therapeutics for serious haematologic diseases. In the company's own words, repeated verbatim in every press release and in the Compensation Discussion and Analysis of the 2026 proxy statement: Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Independent characterisation. Disc is best understood not as a discovery platform company but as a mechanism-directed asset aggregator with deep domain expertise in a single organ system. Management — drawn heavily from Acceleron Pharma, which built a comparable franchise around TGF-β superfamily biology in haematology before its $11.5 billion sale to Merck — has applied a repeatable playbook: identify a de-risked or partially de-risked molecule whose originator has deprioritised it, secure global rights at modest upfront cost with back-loaded milestones, and redirect it into a rare or under-served haematologic indication where the biology is mechanistically obvious and the regulatory path is short.

All three clinical assets were sourced this way. Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that Roche advanced through large schizophrenia trials — generating a safety database of more than 4,000 clinical trial participants — before abandoning the CNS indication; Disc licensed it in May 2021 and repositioned it against erythropoietic porphyrias, where reducing glycine supply to developing erythroblasts throttles the accumulation of the toxic photoactive intermediate protoporphyrin IX (PPIX). Selcodebart (DISC-0974), an anti-hemojuvelin monoclonal antibody in-licensed from AbbVie, suppresses hepcidin to liberate iron in anaemia of inflammation. DISC-3405, an anti-TMPRSS6 (matriptase-2) monoclonal antibody in-licensed from Mabwell Therapeutics in January 2023, does the mirror image — inducing hepcidin to restrict iron in diseases of excess erythropoiesis or iron overload. The elegance of the portfolio is that DISC-0974 and DISC-3405 are pharmacological opposites acting on the same axis, giving Disc coverage of both hepcidin-deficient and hepcidin-excess disease states.

Business model and revenue model. Disc has generated no product, service, subscription or licensing revenue in any fiscal year reported. Its consolidated statements of operations show no revenue line whatsoever for FY2021 through FY2025 and for the six months ended 30 June 2026. The company is financed entirely by equity issuance, supplemented by a term-loan facility from Hercules Capital. The intended revenue model is direct commercialisation: Disc retains worldwide rights to bitopertin and has already built marketing, market access, medical science liaison and field sales infrastructure in the United States in anticipation of launch, a build-out the compensation committee credited as a 2025 corporate achievement. One small out-licensing arrangement exists — a December 2024 out-license of legacy Gemini intellectual property to Oak Bay Biosciences, Inc. — but it is immaterial to the investment case.

Value chain position. Disc occupies the clinical development and (prospectively) commercial layers only. It owns no manufacturing. Drug substance and drug product are produced by contract development and manufacturing organisations; the 2025 corporate goals explicitly include "initiated CMC technology transfer to Phase 3 CDMO" for both DISC-0974 and DISC-3405, confirming an outsourced supply chain. Clinical trials are run through contract research organisations, a dependency the company identifies as a risk factor. Upstream, Disc is a licensee dependent on Roche, AbbVie and Mabwell for underlying rights; downstream, if approved, bitopertin would be distributed through specialty pharmacy and centre-of-excellence channels typical of ultra-rare disease.

Customer types and end-markets. Ultimately: haematologists, hepatologists and dermatologists treating protoporphyria at porphyria centres of excellence; haematologist-oncologists treating myelofibrosis and polycythemia vera; and, in later-stage pipeline ambitions, gastroenterologists (anaemia of inflammatory bowel disease) and sickle cell disease specialists. Payers are commercial insurers and CMS in the US, and national reimbursement bodies in Europe. Management commentary at the Wells Fargo healthcare conference in September 2026 indicated a launch strategy focused on engaged, diagnosed patients and centres of excellence — the classic ultra-orphan concentration play.

Stated strategy — verbatim themes. The corporate positioning statement repeated in every filing is the strategic thesis in miniature: "building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis." Three words in that sentence carry the strategy. Portfolio — Disc is explicitly not a single-asset company and resists being valued as one. Fundamental biological pathways — the company selects targets where the mechanism is causally upstream of the disease rather than symptomatic. Wide spectrum — each mechanism is intended to franchise across multiple indications rather than serve one.

Management's own framing of the 2025–2026 arc, from the January 2026 objectives release: "2025 was a transformative year for Disc, marked by strong execution across our portfolio and meaningful progress toward becoming a fully integrated clinical and commercial organization." And, looking forward: "We are preparing to execute a successful US launch of bitopertin for EPP while continuing enrollment in the global APOLLO confirmatory study." That second statement has since been overtaken by the CRL. The revised framing, from the September 2026 RESTORE-PV release, marks a deliberate rebalancing: "we have strengthened our commitment to hematologic oncology and now have two programs advancing toward potential pivotal development in myeloproliferative neoplasms."

That sentence is the single most strategically significant piece of management commentary in the last eighteen months. It signals that Disc is repositioning from an ultra-rare-disease company with an oncology option into a myeloproliferative neoplasm company with an ultra-rare-disease asset. The audience for that message is investors who marked the stock down on the CRL.

Announced strategic initiatives, last 24 months.

Sustainability, ESG and cost programmes. No emissions targets, sustainability-linked initiatives, formal ESG programme or announced cost-reduction programme have been disclosed. There has been no restructuring or workforce reduction following the CRL.

Medium-term financial targets and guidance. Disc provides no revenue, margin or earnings guidance — appropriate for a pre-revenue company. The only recurring quantitative guidance is cash runway, currently "into 2029" based on the 30 June 2026 position. Operational guidance as of the Q2 2026 report: APOLLO topline in Q4 2026; CRL response submission and an FDA decision by mid-2027; additional RALLY-MF data in Q4 2026 with an end-of-Phase-2 FDA meeting by year-end; RESTORE-PV update and Phase 1b SCD initial data by end of 2026; DISC-0974 IBD initial data in 2027; and the prospect of advancing two additional programmes into pivotal development in 2027.

Disc Medicine has no approved products and no commercial offerings anywhere in the world. Every asset described below is investigational. There is no disclosed pricing model for any candidate; pricing has not been announced for bitopertin notwithstanding launch preparations.

Bitopertin — oral GlyT1 inhibitor (heme synthesis modulator)

Selcodebart (DISC-0974) — anti-hemojuvelin monoclonal antibody (hepcidin suppression)

DISC-3405 — anti-TMPRSS6 monoclonal antibody (hepcidin induction)

DISC-0998 and early-stage programmes

Currency: USD. Fiscal years ended 31 December. Sources: FY2022 earnings release (FY2021, FY2022), FY2025 earnings release and Form 10-K (FY2023, FY2024, FY2025).

Income statement

Notes and caveats. FY2021 and FY2022 EPS are computed on the pre-merger private-company capital structure and are not comparable to subsequent years; the December 2022 reverse merger and the concurrent 1-for-10 reverse split reset the share count. Margin rows are zero placeholders because no revenue exists; they are not meaningful. Disc reports no depreciation and amortisation line of consequence — non-current assets were $2.981 million at 31 December 2025 — so operating loss is used as the EBITDA proxy. Revenue CAGR is undefined.

Balance sheet

Flagged as unverified, not zero. Accumulated deficit for FY2024 is as disclosed in the FY2024 Form 10-K ($298.0 million); FY2025 is derived by adding the FY2025 net loss of $212.184 million, giving approximately $510.2 million. FY2021–FY2023 accumulated deficit not retrieved. Non-current liabilities are used as a proxy for the Hercules term loan carrying value; the FY2025 10-K does not break out non-current liabilities in the summary balance sheet released with earnings, and a portion may relate to non-debt items. Goodwill and intangibles are recorded at nil: the Gemini transaction was accounted for as a reverse recapitalisation rather than a business combination, and all in-licensing payments have been expensed to R&D.

Cash flow

Dividends paid and buybacks are genuinely nil: Disc has never declared a dividend and has no repurchase authorisation. FY2022 equity proceeds combine $89.5 million net from the Gemini merger with the $53.5 million concurrent financing. FY2023 reflects the $62.5 million registered direct offering. FY2024 debt reflects $27.6 million of net proceeds received under the Hercules Loan Agreement through 31 December 2024. FY2025 equity reflects the January ($243.3 million net) and October ($211.0 million net) underwritten offerings.

Ratios

Interpretation and caveats. ROE for FY2021 is not meaningful (negative equity); ROE for FY2022 is distorted by the recapitalisation and is shown as a placeholder. ROIC, interest coverage, asset turnover and cash conversion cycle are all undefined for a pre-revenue company with no invested-capital return, no operating profit to cover interest, no sales to turn assets against, and no receivables, inventory or payables cycle in the commercial sense. Net debt to EBITDA is shown as the ratio of net cash to the EBITDA loss and is presented as a positive number representing years of loss coverage from the net cash pile — at FY2025 the company held approximately 3.2 years of current-run-rate operating losses in net cash, consistent with management's "runway into 2029" guidance.

Interim results — H1 2026

Commentary on trends, inflections and drivers

Expense trajectory. The defining financial fact of Disc Medicine over five years is the 6.8-fold increase in R&D expense from $25.2 million in FY2021 to $170.6 million in FY2025, and the 11.3-fold increase in G&A/SG&A from $5.8 million to $65.4 million over the same period. Three distinct inflections are visible. The first, in FY2023, reflects the transition from a single Phase 2 programme to a multi-asset clinical portfolio — R&D more than doubled from $33.4 million to $69.3 million as AURORA, BEACON and two DISC-0974 Phase 1b/2 studies ran concurrently. The second, in FY2025, is the largest: R&D rose 76% year over year, driven by the initiation of the Phase 3 APOLLO trial, bitopertin registrational-scale drug manufacturing, the RALLY-MF Phase 2 study, initiation of two DISC-3405 patient studies, increased headcount, and $23.0 million of licence milestone payments ($10.0 million to Roche on APOLLO initiation, $10.0 million to Mabwell on first DISC-3405 patient dosing, $3.0 million to AbbVie on first DISC-0974 Phase 2 patient dosing). The third inflection is in SG&A, which nearly doubled in FY2025 to $65.4 million as Disc built marketing, market access, medical science liaison and field sales organisations in anticipation of a bitopertin launch.

The commercial-build overhang. The SG&A build was undertaken on the assumption of a 2026 launch, an assumption the February 2026 CRL invalidated for at least fifteen months. H1 2026 SG&A of $41.8 million against H1 2025 of $27.3 million shows the organisation has not been substantially unwound — the company has continued to carry launch-ready commercial infrastructure through a period in which no product can be sold. Management has framed this as retained optionality. It is nonetheless a real cash cost of approximately $80 million annualised for a capability that generates nothing until at least mid-2027. Notably, Q2 2026 R&D of $46.9 million was essentially flat against Q2 2025's $46.3 million despite portfolio expansion, because the prior-year quarter included the $10.0 million Roche milestone and because bitopertin manufacturing costs have declined. Underlying R&D growth is therefore steeper than the headline suggests.

Other income. Interest and investment income has become a material offset, rising from a $5.0 million net expense in FY2021 to $24.2 million of net income in FY2025, reflecting the growth of the marketable securities portfolio. At H1 2026 run-rate, other income of $11.7 million annualises to roughly $23 million, partially offset by interest expense on the Hercules facility. This income is a direct function of the cash balance and rate environment and will decline as the cash is consumed.

Balance sheet and funding. Disc has been an opportunistic and, so far, well-timed equity issuer. It raised $243.3 million net in January 2025 into strength following the successful Type C meeting, and $211.0 million net in October 2025 immediately after receiving the CNPV — the two most favourable windows of the past two years. Both raises were completed before the February 2026 CRL. The result is a balance sheet carrying $717.7 million at 30 June 2026 with only modest debt, giving runway into 2029 and, critically, removing financing risk from the APOLLO readout. Share count has grown from 22.3 million weighted-average in FY2023 to 38.6 million in H1 2026, dilution of roughly 73% over two and a half years — the price of that de-risking.

The increase in non-current liabilities from $30.4 million at 31 December 2025 to $60.5 million at 30 June 2026 indicates an incremental draw of approximately $30 million under the Hercules facility during H1 2026, consistent with the option to draw an additional $80.0 million on or before 15 December 2026. Cash declined only $73.4 million in H1 2026 against a $123.0 million net loss, the gap bridged by non-cash stock compensation and the debt draw.

Cash burn and runway sensitivity. Annualising H1 2026 operating expenses gives roughly $269 million of gross spend. Against $717.7 million of liquidity plus up to $170 million of undrawn Hercules capacity, the "into 2029" guidance appears conservative if — and only if — the company does not add a further Phase 3 programme. The 30 July 2026 commentary that Disc could be "positioned to advance two more programs into pivotal-stage development in 2027" is precisely the scenario that would consume that cushion. Investors should read the runway guidance as contingent on the current development plan, not on the plan management has signalled it wants to pursue.

Management guidance

Disc provides no financial guidance beyond cash runway. As of the Q2 2026 report, the company expects its $717.7 million of cash, cash equivalents and marketable securities to fund operational plans into 2029. Operationally, management has guided to:

Consensus growth expectations

The observable consensus datapoints are a Strong Buy rating from thirteen analysts and a mean twelve-month price target of $102.58, implying 46.4% upside from the 11 September 2026 close. Consensus expects continued losses through at least FY2027; the Q2 2026 consensus EPS estimate of −$1.77 against an actual of −$1.54 indicates the street is modelling quarterly losses in the $1.50–$1.80 per share range.

Bull case

1. APOLLO succeeds and delivers traditional approval, not accelerated approval — a strictly better outcome than the January 2026 base case. The June 2026 Type A meeting secured FDA alignment that a successful APOLLO can support traditional approval. Traditional approval eliminates post-marketing confirmatory obligations, produces a stronger label, and materially improves the payer negotiation. The trial is fully enrolled at N=183, completed ahead of schedule, and passed a blinded sample-size re-estimation without adjustment — three independent indications of execution quality. The FDA has already conceded the pharmacology; the remaining question is whether a demonstrated PPIX reduction translates into measurable light tolerance, and the HELIOS open-label extension presented at EHA in June 2026 showed exactly that translation, with sustained PPIX reduction accompanied by significant improvement in light-tolerance measures.

2. The myeloproliferative neoplasm franchise is being systematically under-credited. With roughly $2.0 billion of enterprise value and the substantial majority of it attributed to bitopertin, the market is assigning modest value to two programmes that have both now produced clinical proof of concept. Selcodebart delivered a 56% major and 72% overall anaemia response rate in MF, effective regardless of transfusion status or JAK inhibitor use, with composition-of-matter protection to 2041. DISC-3405 reduced mean phlebotomy events from 4.0 to 0.6 per 26 weeks with 61.5% of patients entirely phlebotomy-free, in a PV population of approximately 150,000 US patients. Both are heading to pivotal-stage decisions within twelve months. Management's September 2026 language — two programmes advancing toward pivotal development in myeloproliferative neoplasms — is a deliberate repositioning of the equity story away from single-asset dependence, and it is grounded in data rather than aspiration.

3. The financing risk that usually accompanies a binary readout has been eliminated. $717.7 million of liquidity, guided runway into 2029, up to $170 million of undrawn non-dilutive capacity, a single bullet debt maturity in December 2029, and net cash covering roughly 27% of the current share price. Management raised $454.4 million in 2025 at prices well above the post-CRL trough — before the CRL. Disc will not be a forced seller of equity at any point before the mid-2027 decision, which is a structurally unusual position for a company facing a Phase 3 readout and materially changes the risk-reward asymmetry.

Bear case

1. The CRL revealed a fundamental evidentiary problem that APOLLO may not solve. The FDA did not question whether bitopertin lowers PPIX. It questioned whether lowering PPIX makes patients better. AURORA and BEACON, both of which measured sunlight-exposure endpoints, failed to demonstrate the association. APOLLO measures the same category of endpoint in the same disease with the same drug. The trial is larger and better powered, but the hypothesis under test is the one that has already failed to produce a convincing signal twice. Meanwhile, dersimelagon — a mechanistically inferior, purely photoprotective agent — has already demonstrated a statistically significant placebo-adjusted improvement in daily sunlight exposure of 23.19 minutes in Phase 3 and filed its NDA in June 2026. If the competitor can hit the clinical endpoint and Disc cannot, the mechanistic superiority argument becomes commercially irrelevant.

2. Every market Disc is entering has acquired a well-capitalised incumbent within the last twelve months. In EPP, LEO Pharma paid up to $435 million for dersimelagon in August 2026 and brings a dedicated dermatology commercial organisation to a market where the existing incumbent, Clinuvel, generates over $100 million with an eight-weekly implant. In PV, the FDA approved rusfertide on 28 August 2026 with a 76.9% Phase 3 response rate, giving Takeda first-mover status in the hepcidin pathway before DISC-3405 has completed Phase 2 — and Silence Therapeutics' divesiran hit its Phase 2 primary endpoint two weeks earlier with an 88% versus 19% response and a dosing interval of twelve weeks against DISC-3405's two to four. Disc is now third to the TMPRSS6 target and behind on both approval timing and convenience. Approximately $170 million of annual R&D is being deployed into three markets where someone else got there first.

3. The cost base has been built for a company that does not yet exist, and the runway guidance assumes a plan management has said it will not follow. SG&A doubled to $65.4 million in FY2025 and ran at $41.8 million in H1 2026, sustaining marketing, market access, MSL and sales organisations for a product that cannot generate a dollar before mid-2027 at the earliest — and never, if APOLLO misses. No restructuring has been announced. Total H1 2026 operating expenses of $134.6 million annualise to $269 million. The "runway into 2029" figure holds only if Disc does not advance additional programmes to pivotal stage — precisely what management stated in July 2026 it intends to do in 2027. Two additional Phase 3 programmes would compress the runway substantially, and would have to be funded from a share count that has already grown 73% in two and a half years.

Key catalysts and monitorables — next twelve months

Analyst verdict

Disc Medicine is a well-run company that has made one large bet, had it partially rejected, and been given a second and arguably better chance to make it. That is the whole investment case, and it should be evaluated as such rather than as a diversified pipeline story.

The February 2026 CRL was the most benign form of rejection available. The FDA accepted the pharmacology outright — bitopertin lowers protoporphyrin IX, and the biology is plausible — and rejected only the inference from biomarker to benefit. The June Type A meeting then converted the setback into an upgrade: a successful APOLLO now supports traditional approval rather than the accelerated approval originally sought, eliminating confirmatory obligations. Management's execution through this period has been genuinely good. APOLLO enrolled ahead of schedule at N=183, the sample-size re-estimation required no change, and $454.4 million was raised at favourable prices before the bad news arrived. The company enters its defining readout with $717.7 million, no financing pressure, and a clean debt profile maturing in 2029.

Against that, three things should temper enthusiasm. APOLLO tests the same hypothesis that two prior trials failed to establish convincingly. Every one of Disc's three markets acquired a well-funded incumbent in the last twelve months — LEO/Tanabe in EPP, Takeda in PV, and Silence close behind with better dosing. And roughly $80 million of annualised SG&A is being spent on a commercial organisation with nothing to sell.

The myeloproliferative neoplasm franchise is real and under-priced, but it is eighteen to twenty-four months from pivotal data. Between now and Q4 2026, this is a single-catalyst equity trading at a 46% discount to consensus target with a beta of 2.05. Position sizing, not conviction, is the operative question. Rating stance: high-conviction, high-variance; not a core holding.

End of dossier. Prepared 12 September 2026 from publicly available sources. Where sources conflict — notably institutional ownership percentages and Clinuvel's reporting currency — both readings are presented and the discrepancy noted. This document is for informational purposes and is not investment advice.

Litigation, regulatory actions, restructurings and layoffs.* None disclosed in the period other than the February 2026 Complete Response Letter, which is a regulatory action but not an enforcement action. No securities class action has been reported following the CRL — notable given the share-price decline, and worth continued monitoring.